Renovacor, Inc.

Having carefully reviewed the Company's heart failure programs, a top five pharmaceutical firm has stated its intention to invest in and help fund Renovacor.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Penn Valley, PA, US
  • Currency USD
  • Founded 1013
  • Employees 3
  • Website renovacorinc.com

Company Summary

Renovacor is a privately held biotechnolgy company whose mission is to develop improved therapies for heart failure, a debilitating and often lethal condition that afflicts more than five million Americans. Renovacor has amassed three promising programs from Temple and Duke universities, two of which involve gene therapy and the third being a small molecule program. A top 5 pharma company has stated its intention to invest in the Company.

Team

  • Richard Driansky
    Chief Executive Officer

    Mr. Driansky is a versatile executive with experience at big pharma and small biotechs. A lawyer by training, he was General Counsel of Rhone-Poulenc Rorer. He later founded and served as CEO of Octagen, a hemophilia company. Octagen's lead drug was sold to its long term pharmaceutical partner after completion of phase II human trials. An application for approval of the drug is pending before the FDA. Investors received an excellent return.

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free